YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe

YERVOY®(ipilimumab) ReceivesYERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe PR Newswire PARIS, France, November 8, 2013 Yervoy, an innovative immuno-oncology therapy that has demonstrated [1] [2] durable long-term survival in some patients, , is now approved for use in previously-untreated patients Bristol-Myers Squibb today announced that the European Commission ®(EC) has approved YERVOY (ipilimumab) for the first-line treatment of [3]adult patients with advanced (unresectable or metastatic) melanoma. When initially approved in Europe in July 2011 for the treatment of adult patients with previously-treated advanced melanoma, ipilimumab represented the first major treatment advance in this disease in more than 30 years, providing the first overall survival benefit ever seen in the [1]treatment of metastatic melanoma in a phase III study. "This first-line approval of ipilimumab is important news for the many people with advanced melanoma across Europe who have not received prior treatment. Despite some advances in the first-line treatment of advanced melanoma, for many patients there remains a high unmet need for improved survival outcomes," commented Ron Cooper, President, Bristol-Myers Squibb Europe. "The granting of this licence extension underscores the belief in the therapeutic potential of treatments like ipilimumab, which is the first approved therapy from our immuno-oncology pipeline.